The Combined Antibiotic Therapy for Carbapenem Resistant Klebsiella Pneumoniae
NCT ID: NCT03950544
Last Updated: 2019-05-15
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
EARLY_PHASE1
80 participants
INTERVENTIONAL
2019-01-01
2020-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Clinical Efficacy of Combination Therapy Based on High-dose Biapenem in CRKP Infections
NCT04552444
Clinical Outcomes of Hypervirulent Carbapenem-resistant Klebsiella Pneumoniae Infection
NCT06190548
Epidemiological Characteristics and Treatment Protocol for Carbapenem-Resistant Klebsiella Pneumoniae in China
NCT03245632
Epidemiology of Klebsiella Pneumoniae in China
NCT03598543
Clinical and Microbiological Outcomes of Infections Due to Carbapenem-Resistant Gram-Negative Bacteria
NCT01041716
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
2. Separate and purify the BALF. Divide each CRKP into four treatment groups based on meropenem.
3.1 By checkerboard method and microdilution broth method,get the minimal inhibitory concentration (MICS) of two antibiotics,then calculate the fractional inhibitory concentration (FIC) index according to MIC results.
3.2 Observe the effect of two antibiotics on the growth of CRKP by TKA.
4.By the above two invitro experiments, analyze the data of the experimental results and get the best combination therapy based on carbapenems.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
SEQUENTIAL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
only meropenem therapy,
this group is only meropenem therapy as a single antibiotic treatment
Fosfomycin
Fosfomycin and meropenem
Tigecycline
Tigecycline and meropenem
Polymyxin B
Polymyxin B and meropenem
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Fosfomycin
Fosfomycin and meropenem
Tigecycline
Tigecycline and meropenem
Polymyxin B
Polymyxin B and meropenem
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* infected with CRKP firstly .
Exclusion Criteria
* Vital signs are unstable
* Unable to tolerate fiberoptic bronchoscopy
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Shanghai 10th People's Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Sheng Wang MD PhD
Director
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Li Hua, master
Role: PRINCIPAL_INVESTIGATOR
Shanghai 10th People's Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Shanghai 10th people's hospital
Shanghai, Shanghai Municipality, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
References
Explore related publications, articles, or registry entries linked to this study.
Du Y, Mu S, Liu Y, Yuan Y, Zhu Y, Ma L, Wang Q, Zhu Z, Liu Y, Wang S. The Genomic Characterization of KPC-Producing Klebsiella pneumoniae from the ICU of a Teaching Hospital in Shanghai, China. Infect Drug Resist. 2022 Jan 11;15:69-81. doi: 10.2147/IDR.S343673. eCollection 2022.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
STPH-ICU-002
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.